Recently, the website of the Shanghai Stock Exchange shows that the IPO of Xuanzhu Biotechnology Co.
, Ltd.
(hereinafter referred to as "Xuanzhu Biotechnology") Science and Technology Innovation Board has been accepted, and the company intends to raise 2.
47 billion yuan
.
It is understood that Xuanzhu Bio is an innovative pharmaceutical enterprise focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is also a subsidiary of Sihuan Pharmaceutical, a Hong Kong-listed company
.
In fact, since the CSRC issued the Draft Several Provisions on the Pilot Domestic Listing of Subsidiaries of Listed Companies in August 2019, listed companies have begun to directly split and list
in the mainland without changing their control.
Among them, in the field of medicine and biology, according to incomplete statistics in the industry, since 2020, more than 10 companies have disclosed plans to split their subsidiaries to go public, including Livzon Group, Dean Diagnostics, Changchun High-tech, Tasly, etc.
, and cover chemical drugs, traditional Chinese medicine, in vitro diagnosis, vaccines and other subdivisions
.
On September 9 this year, according to the Hong Kong Stock Exchange, Lepu Xintai Medical Technology (Shanghai) Co.
, Ltd.
(hereinafter referred to as "Xintai Medical") submitted a prospectus on the Hong Kong Stock Exchange to be listed
on the main board of Hong Kong.
It is understood that Xintai Medical is a subsidiary
of Lepu Medical after Lepu Biology.
It is a large manufacturer of congenital heart disease occlusor products and related surgical supporting products in China
.
It is worth mentioning that this listing is the third time that it has submitted its form after it expired on June 25, 2021 and January 14, 2022
.
On August 15, Kelun Pharmaceutical announced that the company intends to spin off its holding subsidiary, Yili Chuanning Biotechnology Co.
, Ltd.
(hereinafter referred to as "Chuanning Biotechnology") and list on the ChiNext Board of the Shenzhen Stock Exchange
.
The results of the deliberation of the Shenzhen Stock Exchange are: Twining Biologics (IPO) meets the issuance conditions, listing conditions and information disclosure requirements
.
This also means that the IPO of Twining Biotech Growth Enterprise Market has been successfully held
.
It is understood that Twining Bio is one of the main antibiotic intermediate production bases in China
.
According to the prospectus, the company is mainly engaged in the research and development and industrialization of biological fermentation technology, and its products mainly include erythromycin thiocyanate, cephalosporin intermediates, penicillin intermediates and ursodeoxycholic acid (UCDA) crude products, etc.
In addition to ursodeoxycholic acid crude products used in the synthesis of non-antibiotic drugs (forming revenue since 2019), other products are mainly used in antibiotic production
.
.
.
.
.
.
.
However, it should be noted that it is not easy for pharmaceutical companies to split their subsidiaries to go public, and at present, the progress of these pharmaceutical companies that intend to split their subsidiaries to list is different, and the situation is also very different
.
In addition to Xuanzhu Biologics, whose listing has been accepted, some pharmaceutical companies have failed to split and announced the termination of listing
.
In June this year, Baiyunshan issued an announcement that, taking into account the fact that the validity period of the approval issued by the CSRC had expired on June 23 and the changes in the environment of the Hong Kong capital market, it had decided to temporarily suspend the promotion of the
listing of Guangzhou Pharmaceutical Hong Kong stocks.
It is reported that Guangzhou Pharmaceutical belongs to the large commercial sector in the main business of Baiyun Mountain, mainly engaged in pharmaceutical wholesale and retail business, and its business scope includes the wholesale of Western medicine; Retail sale of pharmaceuticals; Wholesale of proprietary Chinese medicines; Wholesale of chemical preparations and biological products (including vaccines); Retail sale of medical supplies and equipment and retail sale of
medical devices.
In 2021, the revenue of Baiyun Mountain's large commercial sector reached 46.
778 billion yuan, accounting for more than 60% of the
overall revenue.
In addition, at the end of August 2020, Yan'an Bikang also issued an announcement that the company received the "Prior Notice of Administrative Penalties" issued by the Shaanxi Regulatory Bureau of the CSRC, and the spin-off matters did not comply with the relevant provisions of the "Several Provisions on the Domestic Listing Pilot of Subsidiaries of Listed Companies", so it planned to terminate the spin-off
.
However, from the overall point of view, spin-off listing has obviously gradually become an important means for the capital market to optimize the allocation of resources, and the industry expects that in the context of pharmaceutical companies constantly adjusting their development logic and structure, as well as wanting to obtain new financing, such spin-off listings will become more and more common, especially in the field of
biomedicine.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
